ClinicalTrials.gg

Program

pegfilgrastim

Also written as “Pegfilgrastim”, “CHS-1701” and “QL0605(PEG-rhG-CSF)”.

Its studies are mostly in Neutropenia · Breast Neoplasms · Lymphoma, Non-Hodgkin · Lymphoma · Febrile Neutropenia, led by 21 companies.

Furthest: phase 4, since Jun 21, 200547 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen150 open or runningphase 4since Jun 21, 2005May 3, 2002none ahead
Dong-A ST30 open or runningphase 3since Jan 19, 2012Jan 19, 2012none ahead
Kyowa Kirin30 open or runningphase 2since Aug 14, 2006Aug 14, 2006none ahead
Adello Biologics20 open or runningphase 1since Apr 12, 2017Apr 12, 2017none ahead
coherus-biosciences-inc20 open or runningphase 1since Apr 8, 2015Apr 8, 2015none ahead
Fresenius Kabi20 open or runningphase 1since Aug 14, 2017Aug 14, 2017none ahead
hangzhou-jiuyuan-gene-engineering-co-ltd20 open or runningphase 2since Aug 6, 2013Jul 2, 2012none ahead
Intas Pharmaceuticals20 open or runningphase 1since Jul 8, 2019Jul 8, 2019none ahead
Merckle20 open or runningphase 1since Apr 18, 2012Apr 18, 2012none ahead
Mundipharma20 open or runningphase 1since Dec 10, 2015Dec 10, 2015none ahead
Qilu Pharmaceutical21 open or runningphase 4since Sep 25, 2024Nov 9, 2020none ahead
Amneal Pharmaceuticals10 open or runningphase 1since Feb 6, 2026Feb 6, 2026none ahead
coherus-oncology-inc10 open or runningphase 1since Mar 2, 2015Mar 2, 2015none ahead
Eurofarma Laboratorios10 open or runningphase 1since Oct 20, 2015Oct 20, 2015none ahead
GC Biopharma10 open or runningphase 3since Feb 6, 2011Feb 6, 2011none ahead
gedeon-richter-plc10 open or runningphase 1since Apr 26, 2017Apr 26, 2017none ahead
gema-biotech-s-a10 open or runningphase 3since Feb 15, 2016Feb 15, 2016none ahead
Hoffmann-La Roche10 open or runningphase 4since May 16, 2016May 16, 2016none ahead
kexing-biopharm-co-ltd11 open or runningphase 3since Nov 25, 2024Nov 25, 2024none ahead
nanogen-pharmaceutical-biotechnology-joint-stock-company10 open or runningphase 1since Dec 12, 2017Dec 12, 2017none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Jan 21, 2014Jan 21, 2014none ahead

Also a collaborator on its studies: lambda-therapeutic-research-ltd, celerion and symyoo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 30 studies since May 3, 2002.

  1. May 16, 2016Hoffmann-La Roche's first study: phase 4 study in Lymphoma, Non-HodgkinNew to Hoffmann-La RocheHoffmann-La Roche · NCT02782845 · 53 enrolled · Colombia, Mexico
  2. Sep 19, 2016Phase 1 study in Healthy VolunteersMundipharma · NCT02912377 · 96 enrolled · Germany
  3. Oct 13, 2016Phase 1 study in LymphomaDong-A ST · NCT02963389 · 27 enrolled · Korea, Republic of
  4. Apr 12, 2017Adello Biologics's first studies: 2 phase 1 studies in Healthy VolunteersNew to Adello BiologicsAdello Biologics · NCT03206229, NCT03202927
  5. Apr 26, 2017gedeon-richter-plc's first study: phase 1 study in BioequivalenceNew to gedeon-richter-plcgedeon-richter-plc · NCT03146988 · 150 enrolled · United Kingdom
  6. Aug 14, 2017Fresenius Kabi's first studies: 2 phase 1 studies in HealthyNew to Fresenius KabiFresenius Kabi · NCT03251248, NCT03251339
  7. Dec 12, 2017nanogen-pharmaceutical-biotechnology-joint-stock-company's first study: phase 1 study in Breast NeoplasmsNew to nanogen-pharmaceutical-biotechnology-joint-stock-companynanogen-pharmaceutical-biotechnology-joint-stock-company · NCT03376503 · 24 enrolled · Vietnam
  8. May 23, 2019Phase 2 study in Peripheral Blood Stem Cell TransplantationKyowa Kirin · NCT03993639 · 35 enrolled · Japan
  9. Jul 8, 2019Intas Pharmaceuticals's first studies: 2 phase 1 studiesNew to Intas PharmaceuticalsIntas Pharmaceuticals · NCT04015232, NCT04014062
  10. Nov 9, 2020Qilu Pharmaceutical's first study: phase 1 study in HealthyNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT04651036 · 300 enrolled · Germany, United Kingdom
  11. Aug 2, 2021Phase 2 study in Multiple MyelomaKyowa Kirin · NCT05007652 · 64 enrolled · Japan
  12. Sep 25, 2024Phase 4 study in Chemotherapy-Induced Febrile NeutropeniaQilu Pharmaceutical · NCT06616571 · 336 planned · China
  13. Nov 25, 2024kexing-biopharm-co-ltd's first study: phase 3 study in Chemotherapy-Induced Febrile NeutropeniaNew to kexing-biopharm-co-ltdkexing-biopharm-co-ltd · NCT06711523 · 250 enrolled · China
  14. Feb 6, 2026Amneal Pharmaceuticals's first study: phase 1 study in Healthy VolunteerNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT07416955 · 180 enrolled · United States

TargetBeta

CSF3 →CSF3R →read by rule
“A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity”NCIt, by rule
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule

Studies

All 47 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07416955Healthy Volunteer · United States1CompletedAmneal PharmaceuticalsOct 10, 2025180
NCT06711523Chemotherapy-Induced Febrile Neutropenia · China3Active, not recruitingkexing-biopharm-co-ltdJun 30, 2026250
NCT06616571Chemotherapy-Induced Febrile Neutropenia · China4RecruitingQilu PharmaceuticalDec 30, 2025336
NCT05007652Multiple Myeloma · Japan2CompletedKyowa KirinOct 25, 202264
NCT04651036Healthy · Germany, United Kingdom1UNKNOWNQilu PharmaceuticalNov 30, 2021300
NCT04015232Immunogenicity · India1CompletedIntas PharmaceuticalsJun 5, 2018200
NCT04014062Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers · India1CompletedIntas PharmaceuticalsMay 1, 2018144
NCT03993639Peripheral Blood Stem Cell Transplantation · Japan2CompletedKyowa KirinJul 21, 202035
NCT03376503Breast Neoplasms · Vietnam1Completednanogen-pharmaceutical-biotechnology-joint-stock-companyOct 9, 201724
NCT03251339Healthy · New Zealand1CompletedFresenius KabiFeb 5, 2018336
NCT03251248Healthy · Australia1CompletedFresenius KabiMay 8, 2018294
NCT03146988Bioequivalence · United Kingdom1Completedgedeon-richter-plcSep 14, 2017150
NCT03202927Healthy Volunteers · United States1CompletedAdello BiologicsMar 1, 2018102
NCT03206229Healthy Volunteers · United States1CompletedAdello BiologicsJun 2, 2017120
NCT02963389Lymphoma · Korea, Republic of1CompletedDong-A STNov 201827
NCT02912377Healthy Volunteers · Germany1CompletedMundipharmaMay 201796
NCT02782845Lymphoma, Non-Hodgkin · Colombia, Mexico4CompletedHoffmann-La RocheOct 200753
NCT03404752Breast Neoplasms · Argentina3UNKNOWNgema-biotech-s-aJun 2018120
NCT02650973Healthy · United States1Completedcoherus-biosciences-incJun 2016122
NCT02629562Clinical Pharmacology · Germany1CompletedMundipharmaJul 2016172
NCT02589301Neutropenia · Brazil1CompletedEurofarma LaboratoriosMar 2016100
NCT02418104Immunity, Humoral · United States1Completedcoherus-biosciences-incDec 2015303
NCT02385851Bioequivalence · United States1Completedcoherus-oncology-incJul 2015116
NCT02306915Pharmacokinetics · United Kingdom1CompletedMerckleMar 201548
NCT02044276Neutropenia · Germany, Italy, Spain3CompletedTeva Pharmaceutical IndustriesAug 29, 2017101
NCT01923545Chemotherapy Induced Neutropenia · Korea, Republic of2CompletedDong-A STMay 201161
NCT01918241Neutropenia · China2UNKNOWNhangzhou-jiuyuan-gene-engineering-co-ltdJan 2016200
NCT01637493Neutropenia · China1UNKNOWNhangzhou-jiuyuan-gene-engineering-co-ltdFeb 201324
NCT01585649Neuroectodermal Tumors, Primitive, Peripheral · Bulgaria, Czech Republic, Hungary and more1CompletedMerckleJun 201421
NCT01674855Chemotherapy Induced Neutropenia · Korea, Republic of3CompletedDong-A STFeb 201374
NCT01328938Neutropenia · Korea, Republic of3CompletedGC BiopharmaNov 2012177
NCT00364468Neutropenia · Japan2CompletedKyowa KirinMar 2008107
NCT00277160Neutropenia4CompletedAmgenNov 2004852
NCT00261313Breast Neoplasms2CompletedAmgenJun 200780
NCT00124111Breast Neoplasms2CompletedAmgen
NCT00117910Breast Neoplasms3CompletedAmgen
NCT00117897Lymphoma, Non-Hodgkin2CompletedAmgen
NCT00117455Lymphoma, Non-Hodgkin2CompletedAmgen
NCT00117442Breast Neoplasms2CompletedAmgenAug 200461
NCT00115414Breast Neoplasms2CompletedAmgen
NCT00115206Carcinoma, Non-Small-Cell Lung4CompletedAmgen
NCT00115193Lymphoma, Non-Hodgkin2CompletedAmgenAug 200577
NCT00114764Leukemia, Myeloid2CompletedAmgenApr 200484
NCT00094809Colonic Neoplasms2CompletedAmgenMay 19, 2006252
NCT00066092Lymphoma2CompletedAmgenMar 200441
NCT00035620Sarcoma2CompletedAmgenJan 200744
NCT00035594Neutropenia3CompletedAmgenFeb 2004928

How it is read

Names in the registry

  • “Pegfilgrastim”, 13 entries
  • “pegfilgrastim”, 12 entries
  • “CHS-1701”, 3 entries
  • “QL0605(PEG-rhG-CSF)”, 2 entries
  • “lipegfilgrastim”, 2 entries

Codes read as this program: TPI120.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.